3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Endocrine Neoplasia Type 2a
1
Lethal Congenital Contracture Syndrome 2
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
483
pembrolizumab
456
Magnetic Resonance Spectroscopy
420
Carboplatin
327
Cyclophosphamide
315
Biopsy
274
Cisplatin
270
Radiotherapy
244
Paclitaxel
229
Gemcitabine
226
Bevacizumab
214
Nivolumab
189
fludarabine
184
venetoclax
174
Drug Therapy
171
Dexamethasone
158
Blood Specimen Collection
158
Oxaliplatin
154
Injections
152
Capecitabine
152
Fluorouracil
145
Docetaxel
144
Radiosurgery
137
Standard of Care
136
Rituximab
126
Pemetrexed
117
durvalumab
115
atezolizumab
110
Leucovorin
110
Radiation
106
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Vascular Endothelial Growth Factor A
×
1 year
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled